Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra QQQ ETF (QLD) vs Revvity Inc (RVTY) Price & Performance

ProShares Ultra QQQ ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra QQQ ETF vs Revvity Inc — how do they compare? ProShares Ultra QQQ ETF trades at $98.31 (market cap $15.38B), while Revvity Inc trades at $155.03 (market cap $16.98B). The key difference: ProShares Ultra QQQ ETF and Revvity Inc are close in size by market cap, and Revvity Inc pays a 0.18% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 36 Days and Revvity Inc for 12 Days on average.

QLDRVTY
Market Cap
$15.38B$16.98B
Volume
4,844,0851,456,900
Sector
Leveraged / InverseHealth
52-Week High
$100.77$157.36
52-Week Low
$57.16$82.26
Typical Hold Time
36 Days12 Days
Enterprise Value
—$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra QQQ ETF

QLD (ProShares Ultra QQQ ETF) trades at $98.12, down 2.11% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum while oscillators remain neutral. The ETF benefits from 2x leverage on the Nasdaq-100, providing amplified exposure to large-cap tech stocks. Recent institutional buying and media coverage highlight continued investor interest in leveraged tech exposure.

Outlook remains cautiously optimistic given the bullish technical setup and institutional accumulation, though leveraged ETFs carry elevated volatility risks during market downturns. The key opportunity lies in continued tech sector strength, while the primary risk involves amplified losses if the Nasdaq-100 declines significantly.

Revvity Inc

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

QLD
75% Buy25% Sell
Avg holding period · 36 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About ProShares Ultra QQQ ETF

QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.

Read more on QLD →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →